McKenna Mark C.
- SEC CIK
- 0001749623
No open-market purchases or sales filed in the past year.
Current role at each company
- APGE Apogee Therapeutics, Inc.Directoras of Sep 3, 2026
- FRNM Freenome, Inc.Other: Former Directoras of Jul 22, 2026
- SYRE Spyre Therapeutics, Inc.Directoras of May 29, 2026
- NAMS NewAmsterdam Pharma Co N.V.Directoras of Jan 9, 2026
- BBOT BridgeBio Oncology Therapeutics, Inc.Other: Former Directoras of Aug 11, 2025
Show 1 more company
- RXDX Prometheus Biosciences, Inc.Chairman, President and CEOas of Jun 16, 2023
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists McKenna Mark C. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
APGE Apogee Therapeutics, Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2024 (view filing) | Dec 12 | 4 days | McKenna Mark C.Director | PPurchase | +20.0K | $49.54 | +$990.8K | New position20.0K after | 2 lots |
RXDX Prometheus Biosciences, Inc.
Chairman, President and CEO4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2023 (view filing) | Mar 15 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −25.0K | $116.14 | −$2.90M | −31.2%55.1K after | |
| Mar 3, 2023 (view filing) | Mar 1-3 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −11.3K | $125.14 | −$1.42M | −17.0%55.1K after | 2 lots |
| Feb 17, 2023 (view filing) | Feb 15-17 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −63.7K | $120.82 | −$7.69M | −53.6%55.1K after | 3 lots |
| Jan 19, 2023 (view filing) | Jan 17 | 2 days | McKenna Mark C.Chairman, President & CEO | SSale | −25.0K | $118.99 | −$2.97M | −31.2%55.1K after |